High Lp(a): What Can You Do About It?

Learning that you have high lipoprotein(a), or Lp(a), can be frustrating because the number is largely inherited and usually does not fall much with diet, exercise, or weight loss. That can make it seem as though there is nothing useful to do.

There is. The most important goal is not simply to force the Lp(a) laboratory value downward. It is to reduce the overall cardiovascular risk that accompanies elevated Lp(a) by controlling the risk factors that can be changed—especially LDL cholesterol and other atherogenic lipoproteins, blood pressure, diabetes, smoking, physical inactivity, and related factors.

The 2026 ACC/AHA dyslipidemia guideline specifically recommends early, optimal management of modifiable cardiovascular risk factors for people whose Lp(a) is at least 125 nmol/L or 50 mg/dL. It also identifies elevated Lp(a) as a reason to consider more intensive LDL-C lowering according to the person’s overall risk.

First, understand what you can and cannot change

Lp(a) is different from many other cardiovascular risk markers.

Its concentration is determined primarily by variants in the LPA gene, which means a person can eat well, exercise regularly, maintain a healthy weight, and still have a very high Lp(a) level.

The American Heart Association states that lifestyle changes generally do not lower Lp(a) itself. The National Lipid Association similarly describes the effects of diet and physical activity on Lp(a) concentration as minor and variable.

That distinction is important because it prevents two common mistakes.

The first is assuming that a high Lp(a) result must mean someone has lived an unhealthy lifestyle. It does not.

The second is assuming that healthy habits are therefore pointless. They are not.

Lp(a) is only one component of cardiovascular risk. If inherited Lp(a) risk cannot easily be removed, reducing other sources of risk becomes especially valuable.

The main goal is lowering total cardiovascular risk

Elevated Lp(a) does not operate in isolation.

A person with high Lp(a) plus high LDL cholesterol, uncontrolled blood pressure, diabetes, or smoking exposure generally faces a different risk profile than someone with the same Lp(a) concentration and otherwise well-controlled cardiovascular risk factors.

Current guidelines therefore emphasize risk-factor intensification rather than simply chasing the Lp(a) number.

For people with elevated Lp(a), that commonly means paying close attention to:

• LDL cholesterol and non-HDL cholesterol
• ApoB when it adds useful information
• blood pressure
• blood glucose and diabetes
• smoking and tobacco exposure
• physical activity
• dietary quality
• body weight when excess weight is contributing to metabolic risk
• sleep and other cardiovascular health behaviors

The 2026 ACC/AHA guideline describes Lp(a)-related risk as interacting with a person’s other risk factors and recommends early management of lipids, blood pressure, glycemic status, and health behaviors.

LDL cholesterol becomes especially important

One of the most actionable findings after discovering high Lp(a) is often the person’s LDL-C and broader ApoB-containing particle burden.

Elevated Lp(a) is considered a cardiovascular risk-enhancing factor. The 2026 guideline states that its presence should favor more intensive LDL-C lowering and management of other risk factors.

This does not mean everyone with Lp(a) above 125 nmol/L automatically needs the same medication or the same LDL-C goal.

Treatment intensity depends on the bigger clinical picture, including whether the person already has atherosclerotic cardiovascular disease, diabetes or kidney disease, their estimated cardiovascular risk, LDL-C and non-HDL-C concentrations, age, family history, and other risk-enhancing factors.

The practical principle is simpler:

You may not currently have an easy way to eliminate the inherited Lp(a) risk, so reducing exposure to other atherogenic particles becomes particularly important.

Do statins lower Lp(a)?

Not meaningfully.

Statins primarily reduce LDL cholesterol by increasing removal of LDL particles from the bloodstream. They are not Lp(a)-lowering drugs.

Studies summarized in the 2026 guideline indicate that statins may even produce a small average increase in measured Lp(a) in some people. However, the guideline explicitly notes that this modest change does not justify discontinuing statin therapy because the cardiovascular benefit of appropriate LDL lowering is well established.

This distinction matters.

Someone taking a statin might see:

• LDL-C fall substantially;
• overall cardiovascular risk decline; and
• Lp(a) remain similar or increase slightly.

That does not mean the statin has failed.

The treatment is addressing a different and modifiable component of cardiovascular risk.

Do not stop or alter prescribed cholesterol medication because of an Lp(a) result without discussing it with the clinician managing your care.

What about ezetimibe and bempedoic acid?

Several nonstatin medications can lower LDL-C even though they do not meaningfully target Lp(a).

These include ezetimibe and bempedoic acid, among others.

Their potential usefulness for a person with high Lp(a) comes primarily from reducing LDL-related risk rather than directly correcting the elevated Lp(a) concentration.

The 2026 guideline includes these medications among the options clinicians may use when additional LDL-C lowering is necessary according to cardiovascular risk and treatment goals.

Whether any particular medication is appropriate depends on the person’s medical history, current lipid levels, previous treatment response, side effects, drug interactions, and overall cardiovascular risk.

PCSK9 inhibitors can lower both LDL-C and Lp(a)

PCSK9-targeting therapies are unusual because they can substantially lower LDL-C while also producing a modest reduction in Lp(a).

The 2026 guideline reports that PCSK9-directed therapies can lower Lp(a) by approximately 15% to 30% in addition to their much larger effects on LDL-C and ApoB.

For people who already have clinical atherosclerotic cardiovascular disease, elevated Lp(a), and LDL-C or non-HDL-C above guideline treatment goals despite maximally tolerated statin therapy, the 2026 guideline recommends adding a PCSK9 monoclonal antibody with proven cardiovascular benefit when appropriate.

There is an important qualification, however.

PCSK9 inhibitors have been shown to reduce cardiovascular events in appropriate high-risk populations, but their trials were not designed to prove that lowering Lp(a) itself caused the reduction in events. They also produce major reductions in LDL-C.

They should therefore not be described simply as approved Lp(a) treatments.

Does niacin lower Lp(a)?

Niacin can lower the laboratory value, but that does not make it a recommended Lp(a) treatment.

The National Lipid Association reviewed randomized trials in which extended-release niacin reduced Lp(a) by roughly 20% to 25%. However, modern cardiovascular-outcomes trials did not demonstrate additional cardiovascular benefit when niacin was added to statin therapy despite improving several lipid measurements.

For that reason, the NLA states that niacin is not recommended specifically for lowering Lp(a).

This is an important example of a broader principle:

Changing a biomarker is not automatically the same as improving health outcomes.

That principle has become even more important as newer, highly potent Lp(a)-lowering drugs are tested.

Should you take aspirin because Lp(a) is high?

Do not start aspirin solely because an Lp(a) test is elevated without discussing the decision with a healthcare professional.

This is an area where the evidence remains unsettled.

Some secondary analyses and observational studies have suggested that people with high Lp(a) might receive greater cardiovascular benefit from aspirin than other primary-prevention populations. The 2024 National Lipid Association statement suggested individualized shared decision-making about aspirin in some people with elevated Lp(a).

However, those findings have not yet been confirmed by prospective randomized trials specifically designed around elevated Lp(a), and aspirin can cause serious bleeding.

The 2026 dyslipidemia guideline similarly notes the suggestive data but says prospective trials are still needed.

For people who already have established cardiovascular disease, aspirin may be indicated for separate secondary-prevention reasons. For someone without cardiovascular disease, elevated Lp(a) by itself is not a reason to self-prescribe daily aspirin.

Can diet lower high Lp(a)?

Usually not to a meaningful degree.

That can be disappointing, but it changes what diet is intended to accomplish rather than making diet irrelevant.

A heart-supportive dietary pattern can help improve LDL-C, blood pressure, blood glucose regulation, body weight, and other cardiovascular risk factors.

In practical terms, this generally means emphasizing foods such as vegetables, fruits, whole grains, legumes, nuts, seeds, and appropriate sources of unsaturated fat while limiting dietary patterns high in saturated fat, highly processed foods, excess sodium, and added sugars according to individual health needs.

Someone with high Lp(a) should therefore judge dietary changes by their effects on overall cardiovascular health, not by expecting the inherited Lp(a) number to fall dramatically.

Does exercise help high Lp(a)?

Exercise generally does not substantially reduce Lp(a) concentration either.

But regular physical activity remains valuable because it can improve cardiorespiratory fitness, blood pressure, insulin sensitivity, metabolic health, weight management, and overall cardiovascular risk.

The American Heart Association specifically recommends staying physically active as part of risk reduction for people with high Lp(a), even though the activity is unlikely to change the Lp(a) test itself.

This is a useful mindset shift:

You are exercising to improve the cardiovascular system around the Lp(a) risk, not necessarily to change the inherited number.

Smoking becomes an especially avoidable risk

Avoiding tobacco exposure is another straightforward way to reduce modifiable cardiovascular risk.

Smoking damages blood vessels and substantially increases cardiovascular risk independently of Lp(a). Combining a strong inherited risk factor with a powerful avoidable risk factor provides little upside.

For someone who smokes, stopping smoking may therefore be far more important to actual cardiovascular outcomes than finding a supplement advertised as capable of lowering Lp(a).

Evidence-based smoking-cessation support can include behavioral counseling and, when appropriate, FDA-approved cessation medications discussed with a healthcare professional.

Control blood pressure, diabetes, and metabolic risk

High Lp(a) should also prompt attention to cardiovascular risks outside the lipid panel.

The 2026 guideline specifically emphasizes blood-pressure control and glycemic management among the modifiable risks that should be addressed when Lp(a) is elevated.

That does not mean a person with high Lp(a) should try to push every health measurement as low as possible.

Rather, hypertension, diabetes, and other cardiometabolic conditions should be identified and managed according to appropriate clinical guidelines instead of focusing so narrowly on the inherited Lp(a) value that more treatable risks are neglected.

Could a coronary artery calcium scan help?

Sometimes.

Coronary artery calcium, or CAC, scanning uses a low-dose CT scan to identify calcified plaque in the coronary arteries. It can help refine cardiovascular risk when the decision about preventive treatment remains uncertain.

The 2026 ACC/AHA guideline recommends selective CAC use for risk reclassification and notes its usefulness in men age 40 and older and women age 45 and older when additional information would help guide LDL-C and non-HDL-C treatment goals.

A CAC score of zero can be reassuring in the appropriate context, but it does not erase the lifetime implications of high Lp(a), particularly in younger adults who may not yet have developed calcified plaque. The National Lipid Association cautions against interpreting zero calcium as proof that elevated Lp(a) has become irrelevant.

CAC testing is therefore a risk-assessment tool, not an Lp(a) treatment.

When is lipoprotein apheresis used?

Lipoprotein apheresis is a procedure in which blood is circulated through equipment that removes ApoB-containing lipoproteins before the blood is returned to the patient.

It can substantially lower both LDL and Lp(a), but the effect is temporary and repeated procedures are required.

In the United States, its approved Lp(a)-related use is narrow. The National Lipid Association describes an FDA-approved indication for certain high-risk patients with familial hypercholesterolemia and established coronary or peripheral artery disease who continue to have markedly elevated LDL-C and Lp(a) despite maximally tolerated lipid-lowering treatment.

This is not a routine intervention for an otherwise healthy person who discovers an elevated Lp(a) result.

Apheresis is generally managed through lipid specialists or specialized cardiovascular centers.

Are there medications specifically designed to lower Lp(a)?

Several have been developed, but this area changed significantly in September 2026.

As of September 24, 2026, there is no approved medication whose specific indication is to lower Lp(a) and thereby reduce cardiovascular events.

One of the most closely watched candidates was pelacarsen, an antisense therapy designed to reduce production of apolipoprotein(a).

On September 4, 2026, Novartis reported topline results from the phase 3 Lp(a)HORIZON trial involving 8,323 people with established cardiovascular disease and elevated Lp(a). Pelacarsen lowered Lp(a), but the trial did not meet its primary endpoint of reducing major cardiovascular events compared with placebo.

That result does not prove that Lp(a) can never be successfully targeted. Other therapies and clinical-outcomes trials remain under investigation. It does, however, reinforce why impressive reductions in a laboratory marker should not be treated as proof of cardiovascular benefit before outcomes trials are complete.

For a detailed look at the drugs and clinical evidence, see our guide to Lp(a)-lowering treatments and the latest trials.

Should you buy supplements that claim to lower Lp(a)?

Claims about supplements deserve caution.

There is currently no dietary supplement with strong clinical-outcomes evidence showing that taking it specifically to lower Lp(a) reduces heart attacks, strokes, or other Lp(a)-related cardiovascular events.

Some supplements can also interact with medications, affect liver or kidney function, change bleeding risk, or contain doses substantially different from those used in clinical research.

That is especially relevant with niacin. Although niacin is technically a vitamin, high-dose niacin used for lipid modification behaves like a drug, can cause meaningful adverse effects, and is not recommended as an Lp(a)-lowering strategy simply because it can decrease the laboratory value.

A supplement should not substitute for evidence-based cardiovascular risk management.

Your family may need to know about the result

Because Lp(a) is strongly inherited, your test result may provide useful information about more than your own health.

The National Lipid Association recommends cascade screening of first-degree relatives when elevated Lp(a) is identified. First-degree relatives include parents, siblings, and children.

Family members should not assume that they share the same concentration. The purpose of screening is precisely to find out who inherited a high level.

Knowing earlier may allow relatives to address modifiable cardiovascular risk factors before disease develops.

Do you need to keep checking Lp(a)?

Usually not frequently.

Because Lp(a) is predominantly genetically determined, it is much more stable over time than LDL-C or triglycerides. For most people, repeated measurements provide less useful information than monitoring the modifiable risk factors that can actually change.

Repeat testing may still be reasonable in selected circumstances—for example, when the initial measurement occurred during pregnancy or another medical state that could influence the result, when treatment specifically affecting Lp(a) is being used in a research or specialist setting, or when a clinician believes another measurement would change management.

For most people with a clearly elevated result, however, repeatedly checking the same inherited number is less important than acting on the information it has already provided.

A practical checklist after finding out your Lp(a) is high

An elevated Lp(a) result is most useful when it triggers a structured look at the rest of cardiovascular health.

A reasonable discussion with a healthcare professional can include:

1. Confirm what the result means. Review the reported unit—nmol/L or mg/dL—and avoid using fixed internet conversion formulas between the two.
2. Assess overall cardiovascular risk. Consider age, blood pressure, smoking, diabetes, kidney disease, family history, and whether cardiovascular disease is already present.
3. Review LDL-C and non-HDL-C. Elevated Lp(a) may support more intensive attention to these modifiable lipoproteins.
4. Consider ApoB when appropriate. It may identify residual atherogenic particle burden that LDL-C alone does not reveal.
5. Address lifestyle-related risk. Diet, exercise, tobacco avoidance, sleep, weight management, and metabolic health matter even if the Lp(a) number barely changes.
6. Review medications in context. Treatment should target the person’s overall risk rather than the desire to change one laboratory result.
7. Discuss whether further risk assessment is useful. In selected adults, CAC imaging may help clarify preventive-treatment decisions.
8. Tell close relatives. Parents, siblings, and children may benefit from having their own Lp(a) measured.

High Lp(a) is not the same as having no options

High Lp(a) exposes a limitation of the usual idea that every cardiovascular risk factor should be directly “fixed.”

For now, most people cannot substantially lower inherited Lp(a) through lifestyle, and no targeted drug has yet demonstrated the combination of regulatory approval and cardiovascular-outcomes evidence needed to make specific Lp(a) lowering routine care.

But that does not make the result unactionable.

The strongest current strategy is to use high Lp(a) as a reason to take the modifiable parts of cardiovascular risk seriously: LDL and other atherogenic particles, blood pressure, diabetes, smoking, physical activity, diet, and appropriate preventive treatment.

The Lp(a) value may be inherited. The rest of the risk profile often is not.

References

1. Blumenthal RS, Morris PB, Gaudino M, et al. “2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia.” Circulation and Journal of the American College of Cardiology, 2026.
2. Koschinsky ML, Bajaj A, Boffa MB, et al. “A Focused Update to the 2019 NLA Scientific Statement on Use of Lipoprotein(a) in Clinical Practice.” Journal of Clinical Lipidology, 2024.
3. American Heart Association. “Lipoprotein(a).” Cardiovascular patient and professional education resource, accessed 2026.
4. Novartis. “Lp(a)HORIZON Phase III Topline Results for Pelacarsen in Patients With Elevated Lp(a) and Established Cardiovascular Disease.” September 4, 2026.